Neurocrine Biosciences, Inc. (NBIX) News

Neurocrine Biosciences, Inc. (NBIX): $104.49

0.67 (+0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NBIX News Items

NBIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBIX News Highlights

  • NBIX's 30 day story count now stands at 20.
  • Over the past 22 days, the trend for NBIX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about NBIX are TD, AMP and CAH.

Latest NBIX News From Around the Web

Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growth

It hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price...

Yahoo | February 8, 2023

Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday, February 14, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

Yahoo | February 7, 2023

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript February 6, 2023 Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Fourth Quarter and Year End Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. . Please note […]

Yahoo | February 7, 2023

Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Call Transcript

Start Time: 08:00

End Time: 09:02

Neurocrine Biosciences, Inc. (NBIX)

Q4 2022 Earnings Conference Call

February 06, 2023, 08:00 AM ET

Company Participants

Kevin Gorman - CEO

Matt Abernethy - CFO

Eric Benevich - Chief Commercial Officer

Eiry Roberts - Chief Medical Officer

Kyle Gano - Chief Business Development and Strategy Officer

Todd Tushla - VP of IR

Conference Call Participants

Paul Matteis - Stifel

Neena Bitritto-Garg - Citi

Tazeen Ahmad - Bank of America

Brian Skorney - Baird

Phil Nadeau - Cowen & Company

Chris Shibutani - Goldman Sachs

Carter Gould - Barclays

Myles Minter - William Blair

Brian Abrahams - RBC Capital...

SA Transcripts on Seeking Alpha | February 6, 2023

Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly Tumble

Neurocrine reported soaring fourth-quarter profit Monday and issued in-line guidance for Ingrezza. But NBIX stock toppled.

Yahoo | February 6, 2023

If You're in Neurocrine Biosciences Consider Getting Out: Here's Why

Prices declined below $106 in early trading Monday so traders should be out of longs. The On-Balance-Volume (OBV) line has stalled the past three months. The trend-following Moving Average Convergence Divergence (MACD) oscillator is bearish.

Yahoo | February 6, 2023

Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 6, 2023

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided financial guidance for 2023.

Yahoo | February 6, 2023

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | January 31, 2023

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | January 30, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6737 seconds.